| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $393,341 ) |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI168729 | Elucidating mediators of genetic instability in Candida glabrata | 000 | 2 | NIH | 10/25/2023 | $209,973 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI174118 | Identifying drug-resistant Candida species using SuperSelective primer PCR | 000 | 2 | NIH | 10/30/2023 | $183,368 |
| | 2024 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE152512 | Community Project Funding/Congressionally Directed Spending - Construction | 02 | 1 | HRSA | 11/16/2023 | $0 |
| | 2024 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE152512 | Community Project Funding/Congressionally Directed Spending - Construction | 01 | 1 | HRSA | 11/8/2023 | $0 |
| | 2024 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA239716 | Study of Interleukin 33 as a new immunotherapy of lung cancer | 000 | 6 | NIH | 11/1/2023 | $0 |
| | 2024 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE147180 | Community Project Funding/Congressionally Directed Spending - Construction | 03 | 1 | HRSA | 10/11/2023 | $0 |
| | 2024 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE146126 | Community Project Funding/Congressionally Directed Spending - Construction | 04 | 1 | HRSA | 11/16/2023 | $0 |
| | 2024 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T2246942 | Dental Reimbursement Program | 01 | 1 | HRSA | 10/17/2023 | $0 |
| | 2024 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE147180 | Community Project Funding/Congressionally Directed Spending - Construction | 04 | 1 | HRSA | 11/16/2023 | $0 |
| | 2024 | 2021 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI090155 | The molecular basis of the carbapenem resistance epidemic | 000 | 11 | NIH | 10/18/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $26,190,711 ) (Continued on the next page) |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00AI141622 | C5a/C5ar1 signaling in protective immunity during invasive candidiasis | 000 | 3 | NIH | 7/13/2023 | $249,000 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | U19AI142731 | Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents | 000 | 5 | NIH | 4/21/2023 | $6,521,325 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R37CA250661 | Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | 000 | 2 | NIH | 1/30/2023 | $543,694 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI141183 | Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | 000 | 5 | NIH | 2/6/2023 | $1,142,038 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI084385 | I.C.A.R.E. - Integrated Care for Addiction Recovery Expansion | 002 | 3 | SAMHSA | 6/29/2023 | $524,904 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI121080 | CTCF in CD8 T cell homeostasis and anti-viral/tumor immunity | 000 | 7 | NIH | 7/20/2023 | $523,039 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE152512 | Community Project Funding/Congressionally Directed Spending - Construction | 00 | 1 | HRSA | 9/20/2023 | $1,000,000 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T2249945 | Dental Reimbursement Program | 00 | 1 | HRSA | 8/3/2023 | $177,751 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI177342 | Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung disease | 000 | 1 | NIH | 6/6/2023 | $857,555 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79SM084539 | Hackensack Meridian Carrier Clinic Mental Health Awareness in Identifying Disturbances in Emotions Program (AIDE) | 000 | 3 | SAMHSA | 6/8/2023 | $124,655 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI112579 | Tcf1 programs CD8 T cell responses to enhance viral and cancer immunity | 000 | 8 | NIH | 4/19/2023 | $516,631 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI083671 | HMH Youth and Family TREE Program | 000 | 1 | SAMHSA | 6/7/2023 | $539,943 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | UG3OD035546 | Enriching ECHO Cohorts with High-risk Pregnancies and Children with Disabilities (Enriching ECHO) | 000 | 1 | NIH | 8/25/2023 | $2,073,508 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI161013 | Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | 000 | 3 | NIH | 6/22/2023 | $1,276,503 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI109025 | Critical Factors Influencing Echinocandin Resistance in Candidaglabrata | 000 | 11 | NIH | 6/26/2023 | $857,021 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AA030625 | Peptide therapy for alcohol-induced CNS injury | 000 | 1 | NIH | 4/19/2023 | $254,581 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA254274 | Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy | 002 | 4 | NIH | 5/12/2023 | $393,090 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01HL154757 | DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity | 000 | 3 | NIH | 3/31/2023 | $647,809 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245123 | Elucidating the Role of SMAD4 in Colorectal Cancer | 000 | 4 | NIH | 7/7/2023 | $249,000 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | K00CA264409 | Optimizing adherence to lung cancer screening: Applying theory and implementation science to participant engagement | 001 | 3 | NIH | 9/14/2023 | -$1,500 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 03 | 4 | CMS | 8/3/2023 | $0 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 01 | 4 | CMS | 2/10/2023 | $0 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 02 | 4 | CMS | 5/23/2023 | $0 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 00 | 4 | CMS | 12/15/2022 | $1,991,406 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI145436 | Translational approaches to improve understanding and outcome in Tuberculous meningitis | 001 | 4 | NIH | 3/14/2023 | $703,053 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | K00CA264409 | Optimizing adherence to lung cancer screening: Applying theory and implementation science to participant engagement | 000 | 3 | NIH | 8/22/2023 | $94,452 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA263662 | Leveraging Social Media to Increase Lung Cancer Screening Awareness, Knowledge and Uptake in High-Risk Populations | 002 | 3 | NIH | 8/16/2023 | $670,094 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI150765 | Immunometabolic regulations of pulmonary TB pathogenesis by adiposetissue | 000 | 5 | NIH | 12/15/2022 | $764,187 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI168729 | Elucidating mediators of genetic instability in Candida glabrata | 000 | 1 | NIH | 11/9/2022 | $277,372 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI174118 | Identifying drug-resistant Candida species using SuperSelective primer PCR | 000 | 1 | NIH | 11/25/2022 | $269,850 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA239716 | Study of Interleukin 33 as a new immunotherapy of lung cancer | 002 | 6 | NIH | 9/1/2023 | $433,485 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 000 | 1 | NIH | 4/12/2023 | $773,873 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA229979 | Experimental evolution of pancreatic cancer | 000 | 4 | NIH | 8/10/2023 | $249,000 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245488 | Leveraging behavioral science to improve patient understanding of advanced cancer | 000 | 4 | NIH | 12/1/2022 | $249,000 |
| | 2023 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | U19AI142731 | Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents | 001 | 5 | NIH | 5/30/2023 | $0 |
| | 2023 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE146126 | Community Project Funding/Congressionally Directed Spending - Construction | 03 | 1 | HRSA | 4/28/2023 | $0 |
| | 2023 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | CE146126 | Community Project Funding/Congressionally Directed Spending - Construction | 02 | 1 | HRSA | 11/7/2022 | $0 |
| | 2023 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | U19AI171401 | Metropolitan AntiViral Drug Accelerator | 000 | 1 | NIH | 9/14/2023 | $0 |
|
